| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb75b0b19820e3833ebdcb31603b242b |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-02 |
| filingDate |
1998-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_52d4a798d4cf81d44bd8535a24c21502
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89fe86ef343849c34429c7c5318729cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e43278cdc87cef85c1278612db17279c |
| publicationDate |
2000-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2000143699-A |
| titleOfInvention |
Monoclonal antibodies suppress complement-dependent cytotoxicity |
| abstract |
(57) [Summary] (With correction) [Problem] To provide a monoclonal antibody that suppresses complement-dependent cell damage. The monoclonal antibody F16 specifically binds to a dipeptidyl peptidase IV having a specific amino acid sequence and is produced by an F-16 hybridoma. The antibody is a prophylactic agent or treatment for complement-dependent cytotoxicity. Useful as an agent. Further, a compound having an inhibitory activity on complement activity is obtained by a screening method using the above enzyme that binds to the antibody. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011257407-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2007528219-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8062842-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-4884367-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004104216-A3 |
| priorityDate |
1998-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |